A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Anlotinib (Primary)
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Leiomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Acronyms ALTER0203
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 23 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2017.
- 23 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2017.
- 23 Apr 2017 Status changed from recruiting to active, no longer recruiting.